9 Results
Feb/Mar 2008
- C5a Stimulated Cytokine Gene Expression, Intracellular Calcium
Release, and P38 Mapk Phosphorylation in Microglial Cells
Ruihua Chen,Ph.D., Harini Rajan, Xiaoman Yang, Ph.D., Feifei Chen, Sean Turman, and Magdalena Hofer, Ph.D., and Yang Cao, Ph.D. NNRUS, Novo Nordisk Inc.
- Antigen Characterization as a Path to Developing a Better Antibody
Jennifer F. Nemeth, Ph.D., William G. Glass,, Ph.D., Steven C Pomerantz, Ph.D. Centocor Research and Development
- How Then Shall We Screen?
Chaohong Sun, Ph.D. and Philip J. Hajduk, Ph.D. Global Pharmaceutical Research and Development, Abbott Laboratories
- Translational Medicine Perspectives in Drug Discovery and Development
Part II: Target Compound Interaction-The Vastly Neglected Biomarkers
Contributing to Early Clinical Development Failure
Giora Feuerstein MD, Davinder Gill PhD, Charles Dormer, Robert R Ruffolo PhD, J Lynn Rutkowski PhD, Frank S Walsh PhD, Orest Hurko MD Wyeth Research
- Using Flow Cytometers to Enable Translational Medicine Programs
1John Ferbas, M.S., Ph.D. and 2Michelle Schroeder, B.S., M.B.A. 1Director, Departments of Medical Sciences and Clinical Immunology Cellular Immunology Laboratories Group Leader Amgen Inc. 2Director, Departments of Medical Sciences and Clinical Immunology Research Operations Group Leader Amgen Inc.
- Broad-Scale In Vitro Pharmacology Profiling to Predict Clinical Adverse Effects
Steven Whitebread1, Jacques Hamon2, Josef Scheiber1, Alexander Fekete1, Kamal Azzaoui2, Dmitri Mikhailov1 Qiang Lu1 and Laszlo Urban1 1Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Inc., Cambridge, U.S.A. 2Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Basel, Switzerland
- High-Content siRNA Screening for Systems Biology and Target Identification
Eberhard Krausz, Ph.D. High-Throughput Technology Development Studio (TDS), Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG)
- High Throughput Screening Follow-up Studies Using Physiologically Relevant Cells
Eric N. Johnson, Ph.D. Department of Automated Biotechnology Merck & Co., Inc.
- Stem Cells and Cancer: A Multi-Edged Sword
Eve Herold Director of Public Policy Research & Education Genetics Policy Institute